- Home
- APD vs TAK Comparison
APD vs TAK Comparison
Compare APD & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | APD | TAK |
|---|---|---|
| Founded | 1940 | 1781 |
| Country | United States | Japan |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.6B | 57.6B |
| IPO Year | 1994 | 2007 |
Fundamental Metrics
Financial Performance| Metric | APD | TAK |
|---|---|---|
| Price | $291.43 | $18.26 |
| Analyst Decision | Buy | |
| Analyst Count | 13 | 0 |
| Target Price | ★ $308.83 | N/A |
| AVG Volume (30 Days) | 832.2K | ★ 2.1M |
| Earning Date | 04-30-2026 | 05-13-2026 |
| Dividend Yield | 2.39% | ★ 3.24% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $12,037,300,000.00 | N/A |
| Revenue This Year | $6.02 | $0.16 |
| Revenue Next Year | $6.21 | $1.22 |
| P/E Ratio | ★ N/A | $41.25 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $229.11 | $12.99 |
| 52 Week High | $314.87 | $18.90 |
Technical Indicators
Market Signals| Indicator | APD | TAK |
|---|---|---|
| Relative Strength Index (RSI) | 39.80 | 54.56 |
| Support Level | $289.62 | $17.87 |
| Resistance Level | $298.18 | $18.51 |
| Average True Range (ATR) | 5.47 | 0.20 |
| MACD | -1.75 | -0.04 |
| Stochastic Oscillator | 5.20 | 19.32 |
Price Performance
Historical ComparisonAbout APD Air Products and Chemicals Inc.
Since its founding in 1940, Air Products has become one of the leading industrial gas suppliers globally, with operations in 50 countries and 19,000 employees. The company is the world's largest supplier of hydrogen and helium. It has a unique portfolio serving customers across industries, including chemicals, energy, healthcare, metals, and electronics. Air Products generated roughly $12 billion in revenue in fiscal 2025.
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.